Scynexis Reports Interim Results of Ibrexafungerp in P-III (FURI) and (CARES) Studies for the Treatment of Severe Fungal Infections
Shots:
- The P-III (FURI) & (CARES) studies evaluating ibrexafungerp in patients with sev. fungal infections who are intolerant to standard antifungal therapy or experience refractory fungal infections & systemic infections caused by C. auris, respectively
- The results from both studies in 113 study cases showed that 61.1% achieved a CR or PR along with clinical improvement; 22.1% achieved SD; 11.5% were considered no response including 2 patients who died of an underlying condition & 5.3% were considered indeterminate. The results were consistent with prior reported data & support continued patient enrollment
- Ibrexafungerp has received QIDP & FTD from the US FDA for IC including candidemia & IA & has also received ODD for the same indication
Ref: Globenewswire | Image: Scynexis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
